Umoja Biopharma Announces Oversubscribed $100 Million Series C Financing to Advance In Vivo CAR T Pipeline through Key Oncology Clinical Milestones
Summary
Umoja Biopharma Announces Oversubscribed $100 Million Series C Financing to Advance In Vivo CAR T Pipeline through Key Oncology Clinical MilestonesSeries C financing co-led by Double Point Ventures and DCVC Bio Proceeds to support the clinical development of VivoVec derived in vivo CAR T cellsSEATTLE, January 14, 2025-- Umoja Biopharma, Inc. (Umoja), the clinical-stage leader of in vivo cell therapies that aim to realize the full reach and promise of CAR T cells, today announced the closing of a $100 million Series C financing. The proceeds from this financing will enable Umoja to advance its in vivo CAR T cell therapy pipeline, including its lead CD22 UB-VV400 program in multiple oncology and autoimmune clinical studies. Umojas groundbreaking work on in vivo CAR T cell therapies represents a new frontier in oncology and autoimmune treatment. I look forward to collaborating with Umojas exceptional team, investor base, and Board to advance these pioneering programs through clinical development and beyond. We are pleased to announce the closing of our Series C financing with tremendous support from both new and existing investors who recognize Umojas potential to develop the industrys first in vivo CAR T cell generating therapiesall in the hopes of increasing effectiveness, reducing barriers, and expanding access to CAR T cell therapies, commented Andrew Scharenberg, M.D., co-founder and Chief Executive Officer of Umoja Biopharma.